Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: Results of Eastern Cooperative Oncology Group 4593

Journal of Clinical Oncology

Volumn 16, Issue 11, 1998, Pages 3518-3523

  Mehta, Minesh P ^a   Tannehill, Scott P ^a   Adak, Sudeshna ^a   Martin, Linda ^a   Petereit, Daniel G ^a   Wagner, Henry ^a   Fowler, John F ^a   Johnson, David ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; ESOPHAGITIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIMODALITY CANCER THERAPY; MYELITIS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION FIELD; SKIN MANIFESTATION; SURVIVAL RATE;

EID: 0031765167     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.11.3518     Document Type: Article

References (33)

1. Cancer Facts and Figures. American Cancer Society, Atlanta, GA, 1996
2. Komaki R: Combined chemotherapy and radiation therapy in surgically unresectable regionally advanced non-small-cell lung cancer. Semin Radiat Oncol 6:86-91, 1996
3. Cox JD: The role of radiotherapy in squamous, large-cell, and adenocarcinoma of the lung. Semin Oncol 10:81-94, 1986
4. Perez CA: Dose-tumor response and survival studies in radiation therapy of non-small-cell lung cancer. Chest 89:345-346, 1986
5. Sause WT, Scott C, Taylor S, et al: RTOG 8808/ECOG 4588, preliminary analysis of a phase III trial in regionally advanced unresectable non-small-cell lung cancer with minimum three-year follow-up. Int J Radiat Oncol Biol Phys 32:195, 1995 (abstr,. suppl 1)
6. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial. J Natl Cancer Inst 88:1210-1215, 1996
7. Schaake-Koning C, Van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
8. Trovo MG, Minatel E, Veronesi A, et al: Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study. Cancer 65:400-404, 1990
9. Ansari R, Tokars R, Fisher W, et al: A phase III study of thoracic irradiation with or without concomitant cisplatin in locoregional unresectable non-small-cell lung cancer: A Hoosier Oncology Group Protocol. Proc Am Soc Clin Oncol 10:241, 1991 (abstr)
10. Pollinger B, Huber R-M, Fischer R, et al: Prospective randomised trial on the role of HDR-brachytherapy in addition to external-beam radiotherapy for central bronchial carcinoma. Int J Radiat Oncol Biol Phys 36:208, 1995 (abstr, suppl)
11. Robertson JM, Turrisi AT, Hazuka MB, et al: Dose escalation for non-small-cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 32:197, 1995 (abstr, suppl 1)
12. Akerley W, Choy H: Concurrent paclitaxel and thoracic radiation for advanced non-small-cell lung cancer. Lung Cancer 2:S107-S15, 1995 (suppl 2)
13. Roth JA, Mukhopaddhyay T, Zhang WW, et al: Gene replacement strategies for lung cancer. Semin Radiat Oncol 6:105-109, 1996
14. Le Chevalier TL, Arriagada RP, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991
15. Volm M, Hahn EW, Mattern J, et al: Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small-cell lung carcinoma. Cancer Res 48:2923-2928, 1988
16. Withers HR, Taylor JMG, Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27:131-146, 1988
17. Trott KR, Kummermehr J: The time factor and repopulation in tumors and normal tissue. Semin Radiat Oncol 3:115-125, 1993
18. Saunders MI, Dische S: Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small-cell carcinoma of the bronchus. Int J Radiat Oncol Biol Phys 19:1211-1215, 1990
19. Saunders MI, Dische S, Barrett A, et al: Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: An interim report. Br J Cancer 73:1455-1462, 1996
20. Beahrs OH, Henson DE, Hutter RVP, et al: Manual for Staging of Cancer (ed 4): American Joint Committee on Cancer. Philadelphia, PA, Lippincott, 1992, pp 115-119
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Soc 53:457-481, 1958
22. Corvo R, Giaretti W, Sanguineti G, et al: In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol 13:1843-1850, 1995
23. Hall EJ: Time, dose, and fractionation in radiotherapy, in Hall EJ: Radiobiology for the Radiologist (ed 4). Philadelphia, PA, Lippincott, 1994, pp 219-222
24. Ang KK, Jiang GL, Guttenberger R, et al: Impact of spinal cord repair kinetics on the practice of altered fractionation schedules. Radiother Oncol 25:287-294, 1992
25. Saunders M, Dische S, Barrett A, et al: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial. Lancet 350:161-165, 1997
26. Fowler JF: The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62:679-694, 1989
27. Dische S, Saunders MI: Continuous, hyperfractionated, accelerated radiotherapy (CHART): An interim report upon late morbidity. Radiother Oncol 16:65-72, 1989
28. Byhardt RW, Moss WT: The heart and blood vessels, in Cox JD (ed): Moss' Radiation Oncology: Rationale, Technique, Results (ed 7). St Louis, MO, Mosby, 1994, pp 307-319
29. Herskovic A, Orton C, Seyedsadr M, et al: Initial experience with a practical hyperfractionated accelerated radiotherapy regimen. Int J Radial Oncol Biol Phys 21:1275-1281, 1991
30. Byhardt RW, Scott CB, Ettinger DS, et al: Concurrent hyperfractionated irradiation and chemotherapy for unresectable non-small-cell lung cancer: Results of Radiation Therapy Oncology Group 90-15. Cancer 75:2337-2344, 1995
31. Lee J, Scott C, Komaki R, et al: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06. J Clin Oncol 14:1055-1064, 1996
32. Belani CP, Aisner J, Day R, et al: Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy for locally advanced non-small-cell lung cancer: Three-year follow-up. Proc Am Soc Clin Oncol 16:448a, 1997 (abstr 1608)
33. Bonomi P, Kim K, Chang A, et al: Phase III trial comparing etoposide (E) and cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small-cell lung cancer. An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 15:382, 1996 (abstr 1145)